Home > Insider Trading > Filing (0001209191-21-008659)

Filing Details

Accession Number:: 0001209191-21-008659
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-08 21:00:26
Reporting Period:: 2021-02-04

Accepted Time:: 2021-02-08 21:00:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1131146	Stephen Davis	C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-04	31,250	$0.00	43,059	No	4	A	Direct
Common Stock	Disposition	2021-02-04	14,195	$50.61	28,900	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Options (Right to Buy)	Acquisiton	2021-02-04	40,625	$0.00	40,625	$29.59
Common Stock	Employee Stock Options (Right to Buy)	Acquisiton	2021-02-04	40,625	$0.00	40,625	$35.80
Common Stock	Employee Stock Options (Right to Buy)	Acquisiton	2021-02-04	23,750	$0.00	23,750	$21.28

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
40,625	2027-08-03	No	4	A	Direct
40,625	2027-09-07	No	4	A	Direct
23,750	2018-10-15	No	4	A	Direct

Footnotes

On April 29, 2019, the Issuer's Compensation Committee determined that the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above.
The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 40,625 shares.
On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in vesting of the option as to 40,625 shares.
On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in vesting of the option as to 23,750 shares.